HC Wainwright Lowers Earnings Estimates for Xeris Biopharma

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) – Analysts at HC Wainwright lowered their Q3 2026 earnings per share (EPS) estimates for shares of Xeris Biopharma in a note issued to investors on Friday, August 7th. HC Wainwright analyst B. Folkes now anticipates that the company will earn $0.01 per share for the quarter, down from their previous estimate of $0.02. The consensus estimate for Xeris Biopharma’s current full-year earnings is $0.07 per share. HC Wainwright also issued estimates for Xeris Biopharma’s Q4 2026 earnings at $0.00 EPS and FY2027 earnings at $0.11 EPS.

Other equities analysts have also issued reports about the stock. Wall Street Zen lowered shares of Xeris Biopharma from a “strong-buy” rating to a “buy” rating in a research report on Saturday. Weiss Ratings raised shares of Xeris Biopharma from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, July 23rd. Four investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $10.80.

Xeris Biopharma Price Performance

Xeris Biopharma stock opened at $8.39 on Monday. The company has a fifty day simple moving average of $7.77 and a 200-day simple moving average of $6.80. The firm has a market capitalization of $1.45 billion, a price-to-earnings ratio of -76.27 and a beta of 0.66. The company has a quick ratio of 1.50, a current ratio of 2.12 and a debt-to-equity ratio of 17.00. Xeris Biopharma has a 52-week low of $5.25 and a 52-week high of $10.08.

Xeris Biopharma (NASDAQ:XERS) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.19). Xeris Biopharma had a negative net margin of 5.12% and a positive return on equity of 158.10%. The firm had revenue of $92.10 million during the quarter, compared to analysts’ expectations of $90.12 million.

Insider Buying and Selling at Xeris Biopharma

In other news, Director Barbara-Jean A. Bormann-Kennedy sold 16,000 shares of Xeris Biopharma stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $6.09, for a total transaction of $97,440.00. Following the sale, the director owned 126,500 shares of the company’s stock, valued at approximately $770,385. The trade was a 11.23% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Steven Pieper sold 27,600 shares of the stock in a transaction that occurred on Tuesday, July 7th. The stock was sold at an average price of $8.52, for a total value of $235,152.00. Following the completion of the transaction, the insider owned 1,366,053 shares of the company’s stock, valued at $11,638,771.56. The trade was a 1.98% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 266,499 shares of company stock worth $1,996,417. Insiders own 4.35% of the company’s stock.

Hedge Funds Weigh In On Xeris Biopharma

A number of hedge funds have recently modified their holdings of the business. BlackRock Inc. purchased a new stake in Xeris Biopharma in the 2nd quarter valued at about $115,042,000. Vanguard Group Inc. lifted its position in Xeris Biopharma by 13.8% in the fourth quarter. Vanguard Group Inc. now owns 11,186,677 shares of the company’s stock valued at $87,815,000 after buying an additional 1,358,760 shares during the last quarter. Geode Capital Management LLC boosted its stake in Xeris Biopharma by 3.3% during the fourth quarter. Geode Capital Management LLC now owns 4,275,989 shares of the company’s stock worth $33,571,000 after buying an additional 135,815 shares during the period. State Street Corp boosted its stake in Xeris Biopharma by 10.1% during the fourth quarter. State Street Corp now owns 4,116,924 shares of the company’s stock worth $32,318,000 after buying an additional 378,595 shares during the period. Finally, Qube Research & Technologies Ltd increased its position in shares of Xeris Biopharma by 6.0% during the third quarter. Qube Research & Technologies Ltd now owns 3,274,834 shares of the company’s stock valued at $26,657,000 after acquiring an additional 185,063 shares during the last quarter. 42.75% of the stock is currently owned by hedge funds and other institutional investors.

Xeris Biopharma Company Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.